Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular diseases. This highlights the need for greater attention to serum uric acid levels when profiling patients, and suggests that the threshold above which uricemia is considered abnormal is 6 mg/dl, in light of the available evidence. Another important question is whether lowering serum uric acid can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients; the available literature shows a trend toward improvement associated with administration of urate-lowering drugs, in particular for the xanthine oxidase inhibitors. The demonstrated efficacy of urate-lowering therapy on outcomes other than gout flares leads to the consideration that treatment may be beneficial even in the absence of overt gout when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced CKD or cardiovascular risk factors.

Borghi, C., Rosei, E., Bardin, T., Dawson, J., Dominiczak, A., Kielstein, J., et al. (2015). Serumuric acidandthe riskof cardiovascular and renal disease. JOURNAL OF HYPERTENSION, 33(9), 1729-1741 [10.1097/HJH.0000000000000701].

Serumuric acidandthe riskof cardiovascular and renal disease

Mancia, G
2015

Abstract

Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular diseases. This highlights the need for greater attention to serum uric acid levels when profiling patients, and suggests that the threshold above which uricemia is considered abnormal is 6 mg/dl, in light of the available evidence. Another important question is whether lowering serum uric acid can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients; the available literature shows a trend toward improvement associated with administration of urate-lowering drugs, in particular for the xanthine oxidase inhibitors. The demonstrated efficacy of urate-lowering therapy on outcomes other than gout flares leads to the consideration that treatment may be beneficial even in the absence of overt gout when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced CKD or cardiovascular risk factors.
Articolo in rivista - Review Essay
Cardiovascular disease; Hyperuricemia; Renal disease; Serum uric acid; Cardiovascular Diseases; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Renal Insufficiency, Chronic; Risk Factors; Uric Acid; Internal Medicine; Physiology; Cardiology and Cardiovascular Medicine
English
2015
33
9
1729
1741
none
Borghi, C., Rosei, E., Bardin, T., Dawson, J., Dominiczak, A., Kielstein, J., et al. (2015). Serumuric acidandthe riskof cardiovascular and renal disease. JOURNAL OF HYPERTENSION, 33(9), 1729-1741 [10.1097/HJH.0000000000000701].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/200480
Citazioni
  • Scopus 398
  • ???jsp.display-item.citation.isi??? 349
Social impact